Fairvalue-Calculator Fairvalue-Calculator
EN DE

Sinovac Biotech Ltd (SVA) Fair Value & Analysis

Healthcare · US · Market cap $642M

Price$6.47
Fair Value$29.83
Upside+361.1%
Quality80/100
Evidence: Low Range $19.69 – $37.28

Fair value as of: Jun 25, 2026

Analysis

Sinovac Biotech Ltd (SVA) currently trades at $6.47, while our model-based Fair Value estimate is $29.83 — implying the stock looks roughly 361.1% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus …

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Sinovac Biotech Ltd (SVA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $29.83 versus a price of $6.47 — about +361% (undervalued). Model-based estimate, not financial advice.
What is the fair value of SVA?
Our 21-model fair value for Sinovac Biotech Ltd is $29.83 (as of Jun 25, 2026), built from audited fundamentals. The current price is $6.47.
What is the quality score of SVA?
Sinovac Biotech Ltd has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.